CSIR-CCMB India-Specific Sickle Cell Severity Score: What ISS1 and ISS2 Are

Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, have developed an India-specific disease severity score for sickle cell anaemia (SCA). It is built from the records of 171 Indian children treated at the Government Medical College and Hospital, Nagpur. The score comes in two versions, ISS1 and ISS2. Both agreed better with expert clinical judgement than the widely used international Paediatric Severity Score (PSS) did in this study. The researchers say further validation is needed before wider adoption.

What was announced and when

The Hindu published its report on 2 October 2026 (updated 5:47 pm IST, with the article stamped 5:34 pm IST). GKToday's summary is dated 3 October 2026 and says the tool was developed on 2 October 2026. The sources do not give a separate date for when the study was carried out or published in a journal. For this reason, 2 October 2026 is best read as the date of the public report, not a confirmed research completion date.

As of 4 October 2026, the evidence describes a completed study and a tool that is still awaiting wider validation. It does not describe a rollout, a government notification or any scheduled launch.

Why the tool matters

Sickle cell anaemia is caused by a single genetic mutation, yet how severe it becomes varies widely between patients. Some have mild symptoms, while others face repeated hospital admissions and life-threatening complications. Identifying early who is at risk of a severe course can help doctors plan targeted care.

The researchers say existing international scoring systems do not fully match the clinical profile of Indian patients. Disease patterns in India are reported to differ from those in African and Western populations.

How the study was done

• Patients: medical records of 171 children aged up to 18 years with SCA, treated at the Government Medical College and Hospital, Nagpur.
• Reference standard: two experienced paediatricians independently classified each child as mild, moderate or severe.
• Comparison: the PSS, built on international patient data, matched the expert assessments in only about 67% of cases.
• Modification: the score was adapted by adding clinical features common among Indian patients, such as recurrent blood transfusions, severe anaemia needing hospitalisation and acute febrile illnesses.

Source discrepancy: The Hindu says four clinical features were added but names only three. The fourth is not identified in the supplied evidence, so it is not stated here.

ISS1 and ISS2 compared

The practical point of ISS2 is that clinicians could judge severity and decide on management without many laboratory investigations. That could matter where lab access is limited, although the evidence does not test this in such settings.

Findings about Indian patients

The Hindu reports that painful vaso-occlusive crises were the most common complication among the children. Frequent blood transfusions, severe anaemia and recurrent fever-related illnesses led to hospital admissions. It also notes that Indian patients are said to have a milder profile than many African populations, partly because of higher foetal haemoglobin levels. Leg ulcers, pulmonary hypertension and priapism, commonly reported in African populations, are comparatively rare in India. Nutritional deficiencies, infections and environmental stress can still worsen anaemia.

Limits and next steps

• The sample comes from children treated at one hospital, and further validation in larger and more diverse populations is needed before wider use.
• The researchers suggest the model could be relevant to other low- and middle-income countries with similar genetic backgrounds and healthcare conditions. This is a possibility, not a demonstrated result.
• The supplied sources do not name a journal or say whether the study has been peer reviewed.
• Lead researcher Giriraj R. Chandak said the scores could help doctors decide faster on treatment, including the use and dosage of hydroxyurea, one of the primary drugs for SCA.

Exam-relevant background

Science and technology, health

• Sickle cell anaemia is an inherited blood disorder, a haemoglobinopathy. The Hindu attributes it to a mutation in the beta globin gene, which produces abnormal haemoglobin and makes red blood cells sickle-shaped.
• CSIR-CCMB is a laboratory under the Council of Scientific and Industrial Research (CSIR).
• The work is described as part of the CSIR-Sickle Cell Anaemia Mission.
• GKToday also reports that the mission includes an affordable PCR-based molecular test developed by CSIR-CCMB and validated by the Indian Council of Medical Research with 100% sensitivity and specificity. This figure appears only in GKToday among the supplied sources.

These points are useful for science and health current-affairs revision. Nothing in the evidence indicates that any exam will ask about this topic.

Quick answers

What does ISS1 stand for?

India-specific Severity Score. It is the revised model that raised agreement with expert assessment to nearly 83%.

How is ISS2 different?

ISS2 uses easily observable clinical indicators instead of laboratory measurements and reached about 85% overall concordance.

Is the tool already in routine clinical use?

The supplied evidence does not say so. It states that further validation in larger and more diverse populations is needed before wider adoption.